TY - JOUR
T1 - Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis aged 70 years or younger
T2 - A NOTION-2 substudy
AU - Jørgensen, Troels Højsgaard
AU - Thyregod, Hans Gustav Hørsted
AU - Savontaus, Mikko
AU - Bleie, Öjvind
AU - Christiansen, Evald H.
AU - Niemela, Matti
AU - Angerås, Oskar
AU - Gudmundsdóttir, Ingibjörg J.
AU - Laine, Mika
AU - Rück, Andreas
AU - Prendergast, Bernard
AU - Leon, Martin
AU - Søndergaard, Lars
AU - De Backer, Ole
AU - NOTION-2 investigators
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025
Y1 - 2025
N2 - This NOTION-2 sub-study revealed distinct outcomes for transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in low surgical risk patients aged ≤ 70 years with a tricuspid or bicuspid aortic valve stenosis (AS). One year after intervention, the risk of death, stroke or rehospitalization in patients with tricuspid AS was similar after TAVR when compared to SAVR (absolute risk difference: −2.0%; 95% confidence interval (CI): −11.8% to 7.7%) Conversely, in patients with bicuspid AS, TAVR was associated with a significantly higher risk of adverse outcomes (absolute risk difference: 13.8%; 95% CI: 1.2% to 26.3%). These analyses are exploratory, but highlight the importance of tailoring the intervention to the patient's clinical risk profile, life expectancy, native aortic valve morphology and the anticipated risks associated with TAVR or SAVR.
AB - This NOTION-2 sub-study revealed distinct outcomes for transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in low surgical risk patients aged ≤ 70 years with a tricuspid or bicuspid aortic valve stenosis (AS). One year after intervention, the risk of death, stroke or rehospitalization in patients with tricuspid AS was similar after TAVR when compared to SAVR (absolute risk difference: −2.0%; 95% confidence interval (CI): −11.8% to 7.7%) Conversely, in patients with bicuspid AS, TAVR was associated with a significantly higher risk of adverse outcomes (absolute risk difference: 13.8%; 95% CI: 1.2% to 26.3%). These analyses are exploratory, but highlight the importance of tailoring the intervention to the patient's clinical risk profile, life expectancy, native aortic valve morphology and the anticipated risks associated with TAVR or SAVR.
U2 - 10.1016/j.ahj.2025.02.003
DO - 10.1016/j.ahj.2025.02.003
M3 - Journal article
C2 - 39952377
AN - SCOPUS:85219260086
SN - 0002-8703
VL - 284
SP - 67
EP - 70
JO - American Heart Journal
JF - American Heart Journal
ER -